(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $4.06
Utstedt: 12 feb 2024 @ 22:00
Avkastning: 0.12%
Live Chart Being Loaded With Signals
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...
Stats | |
---|---|
Dagens volum | 677 694 |
Gjennomsnittsvolum | 849 600 |
Markedsverdi | 181.50M |
EPS | $0 ( 2024-03-14 ) |
Neste inntjeningsdato | ( $0 ) 2024-05-11 |
Last Dividend | $0.250 ( 2015-09-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.03 |
ATR14 | $0.0670 (1.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Yi Kathy | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Yi Kathy | Sell | 99 634 | Stock Option (Right to Buy) |
2024-02-14 | Stein Steven H | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Orbimed Advisors Llc | Sell | 650 600 | Common Stock |
2024-02-14 | Hayden Donald J Jr | Sell | 10 000 | Common Stock |
INSIDER POWER |
---|
-12.49 |
Last 94 transactions |
Buy: 24 821 782 | Sell: 19 785 944 |
Volum Korrelasjon
Theseus Pharmaceuticals, Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
PXLW | 0.931 |
ADXN | 0.921 |
LIAN | 0.92 |
TNXP | 0.917 |
JFIN | 0.914 |
DSKE | 0.906 |
SPRB | 0.904 |
SRRK | 0.902 |
MEUSW | 0.897 |
LX | 0.895 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Theseus Pharmaceuticals, Korrelasjon - Valuta/Råvare
Theseus Pharmaceuticals, Økonomi
Annual | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.84 |
FY | 2020 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.010 |
Financial Reports:
No articles found.
Theseus Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2014-08-26 |
Last Dividend | $0.250 | 2015-09-08 |
Next Dividend | $0 | N/A |
Payout Date | 2015-09-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.55 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.238 | 1.200 | -7.94 | -9.52 | [0 - 0.3] |
returnOnEquityTTM | -0.245 | 1.500 | -3.83 | -5.75 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 29.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 29.29 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.70 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0156 | -1.500 | 9.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 88.35 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.567 | -1.134 | [0 - 20] |
debtEquityRatioTTM | 0.0163 | -1.500 | 9.93 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -13.58 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.984 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.19 | 1.000 | -0.423 | 0 | [1 - 100] |
returnOnEquityTTM | -0.245 | 2.50 | -2.46 | -5.75 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.378 | -1.134 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00632 | 1.500 | -3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.553 |
Theseus Pharmaceuticals,
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.